SG11201906968YA - Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease - Google Patents

Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease

Info

Publication number
SG11201906968YA
SG11201906968YA SG11201906968YA SG11201906968YA SG11201906968YA SG 11201906968Y A SG11201906968Y A SG 11201906968YA SG 11201906968Y A SG11201906968Y A SG 11201906968YA SG 11201906968Y A SG11201906968Y A SG 11201906968YA SG 11201906968Y A SG11201906968Y A SG 11201906968YA
Authority
SG
Singapore
Prior art keywords
disease
prophylactic
therapeutic agent
inflammatory disease
infectious disease
Prior art date
Application number
SG11201906968YA
Inventor
Kazuo Suzuki
Yosuke Kameoka
Yoshio Yamakawa
Fukuko Kishi
Osamu Suzuki
Minako Koura
Junichiro Matsuda
Original Assignee
A Clip Institute Co
National Institutes Of Biomedical Innovation Health And Nutrition
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Clip Institute Co, National Institutes Of Biomedical Innovation Health And Nutrition filed Critical A Clip Institute Co
Publication of SG11201906968YA publication Critical patent/SG11201906968YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)

Abstract

PROPHYLACTIC AND/OR THERAPEUTIC AGENT OF INFECTIOUS DISEASE OR INFLAMMATORY DISEASE [Problem] To provide a therapeutic method specialized for an inflammatory disease such as intractable vasculitis and an infectious disease, which is different from the previous therapeutic methods, in which a target molecule was not determined, by determining the target molecule useful for treating these diseases. [Solution] According to one aspect of the present invention, a prophylactic and/or therapeutic agent for an infectious disease or an inflammatory disease which contains an antibody recognizing apolipoprotein A2 (APOA2) as an active ingredient is provided.
SG11201906968YA 2017-01-27 2018-01-26 Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease SG11201906968YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017013486 2017-01-27
PCT/JP2018/002576 WO2018139608A1 (en) 2017-01-27 2018-01-26 Preventive and/or therapeutic agent for infectious diseases or inflammatory diseases

Publications (1)

Publication Number Publication Date
SG11201906968YA true SG11201906968YA (en) 2019-08-27

Family

ID=62978497

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201906968YA SG11201906968YA (en) 2017-01-27 2018-01-26 Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease
SG10202108219QA SG10202108219QA (en) 2017-01-27 2018-01-26 Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202108219QA SG10202108219QA (en) 2017-01-27 2018-01-26 Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease

Country Status (9)

Country Link
US (2) US20190367600A1 (en)
EP (2) EP4317431A3 (en)
JP (1) JP7126658B2 (en)
KR (1) KR102581165B1 (en)
CN (1) CN110267680B (en)
AU (1) AU2018213716A1 (en)
CA (1) CA3051826A1 (en)
SG (2) SG11201906968YA (en)
WO (1) WO2018139608A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021085252A1 (en) * 2019-10-30 2021-05-06 国立大学法人 岡山大学 Prophylactic and/or therapeutic agent for inflammatory pulmonary disease
WO2024004580A1 (en) * 2022-06-30 2024-01-04 国立大学法人千葉大学 Method for testing disease progression toward vasculitis or testing risk of covid-19 becoming severe, testing kit, companion diagnostic agent, and testing marker

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US164290A (en) 1875-06-08 Improvement in bedsteads
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
JP2000014383A (en) 1998-07-03 2000-01-18 Igaku Seibutsugaku Kenkyusho:Kk Humanized antibody
FR2801407B1 (en) 1999-11-22 2002-04-12 Roger Felix Sejalon CONTINUOUSLY TRACABLE INVIOLABLE LABEL BRACELET
JP2004081199A (en) 2002-06-25 2004-03-18 Sekisui Chem Co Ltd Method for producing recombinant antibody
US9028822B2 (en) * 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
JP3965147B2 (en) 2003-11-04 2007-08-29 ヤンマー株式会社 Claw shaft attachment / detachment structure of rotary tiller
ATE546734T1 (en) * 2003-12-05 2012-03-15 Cleveland Clinic Foundation RISK MARKERS FOR CARDIOVASCULAR DISEASE
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
AU2008229385A1 (en) * 2007-03-19 2008-09-25 Sirtris Pharmaceuticals, Inc. Biomarkers of sirtuin activity and methods of use thereof
WO2009044723A1 (en) * 2007-10-04 2009-04-09 Biomarker Science Co., Ltd. Method for prediction of effect of interferon therapy and kit for prediction
GB0720976D0 (en) * 2007-10-26 2007-12-05 Medical Res Council Treatment of inflammatory disease
US8225183B2 (en) 2008-09-30 2012-07-17 Lsi Corporation Methods and apparatus for selective data retention decoding in a hard disk drive
US9435813B2 (en) * 2010-05-11 2016-09-06 The General Hospital Corporation Biomarkers of hemorrhagic shock
JP5998318B2 (en) 2010-09-22 2016-09-28 国立大学法人 千葉大学 New vasculitis test method and test reagent
US10196457B2 (en) * 2011-12-19 2019-02-05 National University Corporation Chiba University Artificial immunoglobulin fragment composition
US10208131B2 (en) * 2011-12-19 2019-02-19 National University Corporation Chiba University Artificially produced polyclonal immunoglobulin preparation
CN105637366B (en) * 2013-10-01 2018-05-29 东丽株式会社 Detection method, antibody and the pancreas lesion detection kit of pancreas tumour
JP5685672B1 (en) 2014-07-10 2015-03-18 株式会社山岡製作所 Resin molding method
EP3252474B1 (en) * 2015-01-26 2020-10-21 Toray Industries, Inc. Method and kit for detecting biliary tract cancer
JP6670129B2 (en) * 2015-02-27 2020-03-18 国立大学法人千葉大学 Artificial immunoglobulin fragment composition
WO2016140210A1 (en) * 2015-03-02 2016-09-09 東レ株式会社 Pancreatic dysfunction detection method and detection kit
US9895848B2 (en) 2015-04-22 2018-02-20 The Boeing Company Systems and tooling for manufacturing composite parts and related methods
JP6453199B2 (en) 2015-10-16 2019-01-16 光洋機械工業株式会社 Centerless grinding machine

Also Published As

Publication number Publication date
US20190367600A1 (en) 2019-12-05
EP3581204A4 (en) 2020-12-16
EP4317431A3 (en) 2024-05-22
SG10202108219QA (en) 2021-08-30
JPWO2018139608A1 (en) 2020-01-09
CN110267680A (en) 2019-09-20
WO2018139608A1 (en) 2018-08-02
KR102581165B1 (en) 2023-09-21
US20220213180A1 (en) 2022-07-07
CN110267680B (en) 2023-12-19
CA3051826A1 (en) 2018-08-02
AU2018213716A1 (en) 2019-08-15
EP4317431A2 (en) 2024-02-07
KR20190108152A (en) 2019-09-23
EP3581204A1 (en) 2019-12-18
JP7126658B2 (en) 2022-08-29

Similar Documents

Publication Publication Date Title
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
CL2020001852A1 (en) Processes for the preparation of s-ketamine or s-ketamine hydrochloride or products derived from it. (divisional request 201901066)
CY1123693T1 (en) RNAI AGENTS, COMPOSITIONS AND METHODS OF USING THEREOF FOR THE THERAPEUTIC TREATMENT OF TRANSTHYRETIN (TTR)-RELATED DISEASES
MX2023015185A (en) Protein degraders and uses thereof.
EA201991862A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
EA201890736A1 (en) Modulators of the cow protein of the hepatitis B virus
CY1122265T1 (en) ANTIBODIES AGAINST THEM AND THEIR USES
EA201890394A1 (en) COMPOSITIONS ON THE BASIS OF IRNA FOR TRANSTYRETINE (TTR) AND METHODS OF THEIR APPLICATION FOR THE TREATMENT OR PREVENTION OF TTR ASSOCIATED DISTRIBUTIONS
MX2018003470A (en) Novel anti-mesothelin antibody and composition comprising the same.
MX2022015250A (en) Methods of treating inflammatory diseases.
EA201390156A1 (en) PRODUCTION OF INTER-ALPHA INHIBITOR PROTEINS (IaIp) FROM PLASMA
MX2022006573A (en) Methods of treating inflammatory diseases.
NZ761619A (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
EA201890185A1 (en) METHODS OF TREATMENT OF DISEASES MEDIATED BY GEPSID
EA201300130A1 (en) METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
MX2017009038A (en) Lingo-1 antagonists and uses for treatment of demyelinating disorders.
EA202090401A1 (en) ANTI-TIM-3 ANTIBODIES AND THEIR APPLICATION
EA201890340A1 (en) MONOCLONAL ANTIBODY-INHIBITOR OF FACTOR XIIA
MX2018005154A (en) Single domain antibodies directed against intracellular antigens.
SG11201906968YA (en) Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease
MX2017015279A (en) Exosomes and their use as vaccine.
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
NZ729803A (en) A method for the treatment of motor neuron diseases
MX2022006145A (en) Trem2 antibodies and uses thereof.
MX2017013480A (en) Pharmaceutical composition for treating and/or preventing cancer.